Navigation Links
Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
Date:3/24/2011

PHILADELPHIA, March 24, 2011 /PRNewswire/ -- Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, positive top-line results.  The results will be used to support a New Drug Application (NDA) submission to the Food and Drug Administration (FDA) targeted for the fourth quarter of 2011, based on the study design and specific endpoints that were agreed with the FDA in a Special Protocol Assessment (SPA) agreement. By early 2012, Tarsa also plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).

The ORACAL study is a Phase III multinational, randomized, double-blind, double-dummy, placebo-controlled trial of Tarsa's oral recombinant salmon calcitonin compared to commercially available, synthetic salmon calcitonin administered by nasal spray.  The trial enrolled 565 postmenopausal women with established osteoporosis in six countries.  The ORACAL study's primary endpoint was the percent change in lumbar spine bone mineral density (BMD) after one year of treatment.  Success required that oral salmon calcitonin be superior to placebo and non-inferior to nasal salmon calcitonin spray in increasing BMD at the lumbar spine. Both results were positive and statistically significant.  The trial also assessed the tolerability of oral calcitonin, which was similar to that of calcitonin administered by nasal spray and to placebo. The full data from the study are expected to be presented in a peer-reviewed forum later this year.  

"With these positive Phase III top-line results in hand, we are proceeding with the additional dataset analyses we will need to submit an NDA to the FDA before the end of the year," said David Brand, President and CEO of Tarsa.  "Our tablet has the potential to offer the 30-year record of safety a
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  The Partnership to Fight Chronic Disease (PFCD) released a public ... and a new study analyzing the impact of increased cost sharing ... coalition working to educate policy makers and the public on the ... focused on how the Iowa healthcare exchange ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... 25, 2011 PDI, Inc. (Nasdaq: ... and commercialization services to health care companies, today announced ... 10 pharmaceutical company has been renewed for an additional ... Shared Sales team beginning in September 2011 through March ...
... 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN ) ... who has conducted multiple clinical studies of zinc lozenges for the ... Mr. Eby is a pioneer in the development of zinc ... more than 30 years to the study of zinc and is ...
Cached Medicine Technology:PDI Announces Renewal of Engagement for 7th Consecutive Season 2Adeona Appoints George A. Eby to Scientific Advisory Board 2Adeona Appoints George A. Eby to Scientific Advisory Board 3Adeona Appoints George A. Eby to Scientific Advisory Board 4
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
(Date:12/26/2014)... The US represents the largest market for CRC across ... estimates that sales of branded therapies were $2.23 billion. The ... incidence of the disease, high drug treatment rate, and higher ... sales of CRC therapies over the forecast period will be ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... to Present September,22-24, 2008, WASHINGTON, Sept. ... medical technology companies have been selected to ... presentations offer a unique,business development and information ... the cardiovascular, dental, diagnostics, imaging,metabolic disease/obesity, neurology, ...
... - U.S. Preventive Medicine, Inc.,( http://www.USPreventiveMedicine.com ), the ... Ron Loeppke, M.D., MPH, as Co-Chairman of,the company,s ... researching,the role of primary, secondary and tertiary prevention ... health and,productivity in the workplace, as well as ...
... 1 in U.S. ... ... Inc. and Orphan Therapeutics, LLC announced today that they have,entered into an ... from Orphan Therapeutics., Orphan Therapeutics has initiated a rolling NDA with ...
... 2 The Diversified Agency Services (DAS),unit ... to the position of,Executive Vice President and ... position Sharon will direct the client-centric and,brand-centric ... a,worldwide multidisciplinary resource of specialist agencies that ...
... Sept. 2 September is Cholesterol,Awareness Month. The ... perceived failures in drug trials, Tim Russert,s sudden,death, ... of dyslipidemia in,children have all led to increased ... views these developments as reinforcing the importance of ...
... finding is ,good news, for postmenopausal women taking ... Contrary to previous study results, the cancer prevention ... of cognitive performance, a new study found. ... to tamoxifen in preventing breast cancer recurrence in ...
Cached Medicine News:Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 2Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 3Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 4Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 2Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 3Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 2Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 3Health News:Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group 2Health News:Cholesterol Awareness Month: Americans Urged to Seek Early Intervention 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2
A conservative, cost effective alternative to total knee replacement for patients with osteoarthritis primarily confined to one compartment....
...
... The Maxim Knee employs titanium alloy ... an excellent fixation surface. Biomet's ArCom ... durable and proven bearing material. The ... full inter-changeability. Modular tibial components offer ...
... The Natural-Knee family is a ... with over 14 years of proven ... several innovative features including a proprietary ... fixation in active patients, a unique ...
Medicine Products: